CNI BIOMEDICINE

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Asymchem Tianjin to convene 2nd H-share AGM on June 10 to vote on A-share buyback authorization

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

RemeGen Approves 2.5B RMB Cash Management Plan, Invests 453M with HTSC in Fixed Income Products

Fosun Pharma: Expected to submit NDA by year-end

Baili Tianheng's Innovative Drug SI-B036 Approved for Clinical Trials in Late-Stage Solid Tumors by NMPA

Norges Bank Increases Holding of Tigermed to 813,800 Shares

Hangzhou Therapeutic Biotechnology Proposes Up to 100 Million Yuan Stock Repurchase Plan

Rongchang Biotech Purchases Multiple Wealth Management Products from SPDB Yantai Branch

Fosun Pharmaceutical's Subsidiary Receives Acceptance for Peach Red Four Ingredients Granule Drug Registration Application

Fosun Pharma Industry Acquires Exclusive Option from AriBio

Citi Group Reduced Its Holding of KaiLaiIn H Shares

588250

516820

159859

512290

399441

In 2025, the average number of employees in China's pharmaceutical manufacturing industry is expected to be 1.997 million, a decrease from 2.36 million in 2016. Since the drug review reform in 2015, China's biopharmaceutical industry has experienced rapid development, with a significant increase in the number of innovative drug applications and approvals. However, global tensions and market adjustments have posed challenges, leading to bottlenecks in industry development, and the decline in the average number of employees reflects this trend. Interviews with senior pharmaceutical headhunters provide profound insights into industry changes

腾讯新闻 - 财经

Penghua SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC CSI Biotechnology Theme ETF

300医药

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Medical Service ETF

ICBCCS SSE STAR Biology and Medicine ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

The halo of 'returnees' fades, large companies become internet-oriented, AI offers million-dollar salaries, 30 maxims about 2026 from a senior pharmaceutical headhunter

The CNI BIOMEDICINE ETF (159859) performed outstandingly in trading on March 23, with a net subscription exceeding 300 million shares and a transaction volume of 220 million yuan, making it the leader among similar products. Despite the CNI Biomedicine Index falling by 4.6%, this ETF still attracted capital inflows, demonstrating market confidence in the innovative industry chain. Kaiyuan Securities expects that as the first quarter of 2026 approaches, innovative drugs and related industry chains will continue to maintain an upward trend

The CNI BIOMEDICINE ETF (159859) saw a net subscription of over 300 million shares yesterday, ranking first among the same underlying assets. Institutions: The innovative industrial chain is expected to continue the overall upward trend in performance in Q1

医药生物

161726

160635

Benefiting from the recovery of industry prosperity and favorable policies, more than 50 A-share biomedicine companies are expected to achieve profitability by 2025. According to Wind data, as of January 26, over 90 companies have released performance forecasts, among which 53 companies expect to be profitable, 14 companies expect to double their net profits, 10 companies expect to turn losses into profits, and 14 companies expect to reduce their losses year-on-year

Wallstreetcn

China Merchants CNI BIOMEDICINE Index Fund-A

Penghua CSI Health Care Index Fund(LOF)-A

With the recovery of industry prosperity and favorable policies, over 50 biomedicine A-share companies are expected to report profits in 2025

CNI BIOMEDICINE(399441.SZ)

The halo of 'returnees' fades, large companies become internet-oriented, AI offers million-dollar salaries, 30 maxims about 2026 from a senior pharmaceutical headhunter

The CNI BIOMEDICINE ETF (159859) saw a net subscription of over 300 million shares yesterday, ranking first among the same underlying assets. Institutions: The innovative industrial chain is expected to continue the overall upward trend in performance in Q1

With the recovery of industry prosperity and favorable policies, over 50 biomedicine A-share companies are expected to report profits in 2025